Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IPA

ImmunoPrecise Antibodies Ltd

Dec 12 • 03:23PM ET

0.4000

Dollar change +0.0200
Percentage change 5.26	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP ABCL BGNE ADAP FATE IGMS ANTX CABA ENTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	12.52%	Shs Outstand	30.29M	Perf Week	9.02%
Market Cap	12.42M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	0.00%	Shs Float	21.81M	Perf Month	-14.89%
Income	-20.26M	PEG	-	EPS next Q	-0.07	Inst Own	7.72%	Short Float	1.30%	Perf Quarter	-40.30%
Sales	17.69M	P/S	0.70	EPS this Y	57.53%	Inst Trans	14.10%	Short Ratio	0.50	Perf Half Y	-61.90%
Book/sh	0.77	P/B	0.52	EPS next Y	60.44%	ROA	-41.56%	Short Interest	0.28M	Perf Year	-63.96%
Cash/sh	0.08	P/C	4.89	EPS next 5Y	-	ROE	-66.50%	52W Range	0.32 - 2.60	Perf YTD	-76.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.23%	ROI	-63.68%	52W High	-84.62%	Beta	0.21
Dividend TTM	-	Quick Ratio	0.85	Sales past 5Y	17.44%	Gross Margin	39.34%	52W Low	23.15%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	1.01	EPS Y/Y TTM	-58.39%	Oper. Margin	-60.21%	RSI (14)	46.58	Volatility	13.76% 13.88%
Employees	101	Debt/Eq	0.50	Sales Y/Y TTM	5.44%	Profit Margin	-114.53%	Recom	1.00	Target Price	4.94
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	13.75%	Payout	-	Rel Volume	0.78	Prev Close	0.38
Sales Surprise	-5.98%	EPS Surprise	6.34%	Sales Q/Q	-0.98%	Earnings	Dec 10 BMO	Avg Volume	563.44K	Price	0.40
SMA20	1.86%	SMA50	-15.54%	SMA200	-56.66%	Trades		Volume	398,410	Change	5.26%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$9
Oct-25-21	Initiated	The Benchmark Company	Buy	$12

Dec-10-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 (Business Wire)
Dec-04-24 08:00AM	IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (Business Wire)
Dec-03-24 08:30AM	IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 (Business Wire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-13-24 09:00AM	$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies (Business Wire)
08:01AM	Loading…
Nov-04-24 08:01AM	ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation (Business Wire)
Oct-28-24 07:30AM	ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology (Business Wire) -15.09%
Oct-21-24 09:00AM	ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 (Business Wire)
Oct-10-24 08:10AM	ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design (Business Wire)
Oct-09-24 03:21PM	ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ... (GuruFocus.com) -5.98%
Oct-02-24 08:00AM	ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus (Business Wire)
Sep-26-24 09:00AM	ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments (Business Wire)
Sep-16-24 09:00AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 (Business Wire) -19.12%
Sep-13-24 09:01AM	Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result (GuruFocus.com)
Sep-09-24 09:11AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 (Business Wire)
09:00AM	Loading…
Aug-26-24 09:00AM	ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (Business Wire)
Aug-23-24 08:00PM	ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements (Business Wire)
Aug-19-24 09:00AM	ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology (Business Wire) -5.87%
Jul-29-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 (Business Wire)
Jul-23-24 07:30PM	ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 (Business Wire)
Jul-16-24 08:01PM	ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) -7.14%
Jul-15-24 08:31AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 (Business Wire)
Jun-27-24 08:01AM	ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer (Business Wire)
Jun-25-24 07:02AM	IPAs Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai (Business Wire)
Jun-12-24 07:00AM	ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology (Business Wire)
Jun-10-24 07:15AM	BioStrand, ImmunoPrecise Antibodies Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery (Business Wire) +5.05%
Jun-04-24 07:00AM	IPAs Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) (Business Wire)
Apr-22-24 09:00AM	Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results (ACCESSWIRE)
Apr-12-24 09:00AM	ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments (ACCESSWIRE)
Mar-28-24 07:02AM	InterSystems and IPAs Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications (Business Wire)
07:02AM	Loading…
Mar-20-24 07:02AM	IPA Acquires the Carterra LSA Instrument to Enhance Antibody Discovery and Bolster Its AI Developments (Business Wire)
Mar-15-24 01:48PM	ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript (Insider Monkey) -9.43%
Mar-14-24 12:52PM	IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024 (InvestorPlace)
09:30AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:05AM	IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* (Business Wire)
Mar-08-24 08:30AM	ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology (ACCESSWIRE)
Mar-07-24 07:02AM	IPAs subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology (Business Wire) +16.46%
Mar-04-24 08:01AM	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 (Business Wire) -5.85%
Feb-13-24 08:35AM	ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery (ACCESSWIRE) -8.37%
Jan-10-24 09:00AM	ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms (ACCESSWIRE) +14.08%
Dec-19-23 08:18AM	ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript (Insider Monkey)
Dec-14-23 01:51PM	IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +20.83%
08:01AM	IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* (Business Wire)
Dec-08-23 05:00PM	IPA Announces Closing of $1.265 Million Public Offering of Common Shares (Business Wire)
Dec-07-23 09:00AM	ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14 (ACCESSWIRE)
Dec-06-23 09:00AM	Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today? (InvestorPlace) -24.68%
07:00AM	IPA Announces Pricing of $1.1 Million Public Offering of Common Shares (Business Wire)
Dec-05-23 04:35PM	IPA Announces Proposed Public Offering of Common Shares (Business Wire) -5.78%
Nov-27-23 08:01AM	ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call (Business Wire) +10.00%
Nov-22-23 09:00AM	ImmunoPrecises BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery (ACCESSWIRE)
Nov-13-23 08:32AM	BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research (Business Wire)
Oct-25-23 08:01AM	IPAs Subsidiary, BioStrand, Provides an Update on LENSai (Business Wire) +16.80%
Oct-23-23 08:01AM	IPA Provides Update on Growth Strategy and Recent Share Price Movement (Business Wire) +7.02%
Oct-20-23 09:00AM	Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data (ACCESSWIRE) -8.80%
Oct-13-23 09:45AM	How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research (ACCESSWIRE) -7.24%
Oct-11-23 09:55AM	ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -10.43%
Sep-19-23 08:01AM	ImmunoPrecise Antibodies Announces CFO Transition (Business Wire) +6.70%
Sep-14-23 08:00AM	IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 (Business Wire)
Sep-08-23 08:30AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023 (Business Wire)
Sep-05-23 08:00AM	IPA Announces Board Refreshment (Business Wire) +14.78%
Aug-09-23 09:15AM	IPA Responds to 13D Filing (Business Wire) +8.71%
Jul-14-23 08:10AM	ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research (Business Wire)
Jul-07-23 08:10AM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023 (Business Wire)
Jun-29-23 09:00AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023. (Business Wire)
Jun-16-23 09:30AM	New to The Street Announces TV Corporate Appearances on Episodes 479 and 480 that Start Airing on Saturday, June 17, 2023, at 3:30 PM ET (GlobeNewswire)
Jun-13-23 07:38AM	IPAs Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID) (Business Wire)
Jun-06-23 08:04AM	IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market (Business Wire) -6.46%
May-30-23 08:04AM	IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology (Business Wire) +9.05%
May-17-23 08:04AM	IPA to Present at Jefferies Healthcare Conference 2023 (Business Wire)
Mar-30-23 08:04AM	ImmunoPrecises Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas (Business Wire)
Mar-27-23 08:49AM	European Patent Office to Grant BioKeys Patent Application for Foundational HYFT® Technology (Business Wire)
Mar-23-23 08:04AM	ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates (Business Wire)
Mar-16-23 08:04AM	IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 (Business Wire) -10.13%
Mar-15-23 08:04AM	ImmunoPrecise Antibodies Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio (Business Wire)
Mar-07-23 08:52AM	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023 (Business Wire)
Dec-15-22 08:04AM	IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 (Business Wire) -8.58%
Dec-08-22 08:04AM	IPAs Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs and Accelerates in Silico Drug Discovery Developments (Business Wire)
Dec-05-22 08:04AM	IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022 (Business Wire)
Nov-30-22 08:04AM	IPAs Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies (Business Wire)
Nov-22-22 08:04AM	ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange (Business Wire) -7.45%
Oct-12-22 08:04AM	IPAs Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs (Business Wire)
Sep-14-22 08:31AM	NIAID Confirms IPAs PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75 (Business Wire) -9.85%
08:04AM	IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 (Business Wire)
Sep-08-22 09:03AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022 (Business Wire)
Aug-29-22 08:04AM	Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTopes Efficacy Against SARS-CoV-2 Variants Including BA.5 (Business Wire)
Jul-29-22 08:04AM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022 (Business Wire) -7.03%
Jul-26-22 08:04AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022 (Business Wire)
Jul-12-22 08:04AM	Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPAs PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARSCoV2 (Business Wire)
Jun-25-22 10:52AM	Despite currently being unprofitable, ImmunoPrecise Antibodies (CVE:IPA) has delivered a 44% return to shareholders over 3 years (Simply Wall St.)
May-09-22 08:03AM	IPAs Subsidiary BioStrand Secures Second VLAIO Research Grant (Business Wire) -8.93%
Apr-20-22 08:01AM	IPAs Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern (Business Wire) +7.80%
Apr-14-22 08:01AM	IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings (Business Wire)
Mar-29-22 08:45AM	IPA Announces Agreement to Acquire BioStrand BV Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence (Business Wire) +7.51%
Mar-16-22 08:02AM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022 (Business Wire)
Mar-14-22 08:01AM	IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense (Business Wire)
Mar-09-22 08:01AM	IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 (Business Wire) -7.45%
Mar-08-22 08:01AM	ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET (Business Wire)
Jan-31-22 07:02AM	Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant Moves Towards FDA/IND-Submission (Business Wire) +7.11%
Jan-18-22 08:01AM	ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability (Business Wire)
Jan-17-22 08:02AM	ImmunoPrecise Antibodies Announces Grant of Stock Options (Business Wire)

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPA

ImmunoPrecise Antibodies Ltd

Upgrade your FINVIZ experience